Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing <i>Enterobacterales</i> Bloodstream Infections and/or Ventilator-Associated Pneumonia?

• Main Authors: Milo Gatti (Author), Matteo Rinaldi (Author), Tommaso Tonetti (Author), Antonio Siniscalchi (Author), Pierluigi Viale (Author), Federico Pea (Author)
• Format: Book
• Published: MDPI AG, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

(1) Background: Piperacillin-tazobactam represents the first-line option for treating infections caused by full- or multi-susceptible <i>Enterobacterales</i> and/or <i>Pseudomonas aeruginosa</i> in critically ill patients. Several studies reported that attaining aggressive ph...